TIDMABDX

RNS Number : 7091R

Abingdon Health PLC

07 July 2022

Abingdon Health plc

("Abingdon" or "the Company")

DHSC payment received

York, U.K. 7 July 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, provides an update on the resolution of the outstanding payment with Department for Health & Social Care ("DHSC") .

On 28 June 2022 the Company announced that it had reached a settlement with the DHSC on the outstanding invoices due from DHSC to Abingdon.

Abingdon can confirm that it has today received the GBP6.3m cash payment from DHSC as part of the settlement agreement.

Enquiries:

 
 Abingdon Health plc                                   www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                    Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                        Tel: +44 (0)20 7496 3000 
  Nominated Adviser) 
 Shaun Dobson, Peter Steel, Alex Bond (Corporate 
  Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                 Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com 
 Paul McManus / Phillip                       Mob: +44 (0)7980 541 893 / +44 (0)7867 984 
  Marriage                                                                           082 
 Alice Woodings                                                 Mob: +44 (0)7407 804 654 
 
 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCRRMBTMTIMBLT

(END) Dow Jones Newswires

July 07, 2022 07:51 ET (11:51 GMT)

Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Abingdon Health Charts.
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Abingdon Health Charts.